Beclometasone-aeronativ
Before prescribing inhaled drugs, it is necessary to instruct the patient on the rules for their use, ensuring the most complete delivery of the drug to the desired areas of the lungs. To prevent oral candidiasis, after inhalation you should rinse your mouth and throat with water. To treat candidiasis, topical antifungal drugs can be used while simultaneously continuing therapy with Beclomethasone-aeronativ.
If patients take GCS orally, then Beclomethasone-aeronative is prescribed while taking the previous dose of GCS, and the patients should be in a relatively stable condition. After about 1 to 2 weeks, the daily dose of oral corticosteroids begins to be gradually reduced. The dose reduction scheme depends on the duration of previous therapy and the size of the initial dose of GCS. Regular use of inhaled GCS allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be completely transferred to inhaled therapy), while in the first months after the transition the patient’s condition should be carefully monitored until his pituitary-adrenal system will recover sufficiently to provide an adequate response to stressful situations (for example, injury, surgery, or infection).
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema) that were previously suppressed by systemic drugs may occur.
Patients with reduced function of the adrenal cortex who are transferred to inhalation treatment should have a supply of GCS and always carry a warning card with them, which should indicate that in stressful situations they need additional systemic administration of GCS (after eliminating the stressful situation, the dose of GCS can be repeated reduce). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, often life-threatening for patients, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting beta2-agonists than before.
Beclomethasone aeronative is not intended for the relief of attacks, but for regular daily use. To relieve attacks, short-acting beta2-agonists (for example, salbutamol) are used. In case of severe exacerbation of bronchial asthma or insufficient effectiveness of the therapy, the dose of the drug "Beclomethasone-aeronativ" should be increased and, if necessary, a systemic corticosteroid and/or an antibiotic should be prescribed if the infection develops.
If paradoxical bronchospasm develops, you should immediately stop using Beclomethasone Aeronative, assess the patient’s condition, conduct an examination and, if necessary, prescribe therapy with other drugs. With long-term use of any inhaled corticosteroids, especially in high doses, systemic effects may be observed (see “Side effects”), but the likelihood of their development is much lower than when taking corticosteroids orally. Therefore, it is especially important that when a therapeutic effect is achieved, the dose of inhaled corticosteroids is reduced to the minimum effective dose that controls the course of the disease. At a dose of 1500 mcg/day, the drug does not cause significant suppression of adrenal function in most patients. Due to possible adrenal insufficiency, special care should be taken and regular monitoring of adrenal function indicators when transferring patients taking oral corticosteroids to treatment with Beclomethasone-Aeronativ.
Sharp o. is not recommended.
Particular care should be taken when treating patients with active or inactive forms of pulmonary tuberculosis with inhaled corticosteroids.
It is necessary to protect the eyes from contact with the drug. By washing after inhalation you can prevent damage to the skin of the eyelids and nose.
The Beclomethasone Aeronative canister must not be pierced, disassembled or thrown into fire, even if it is empty. Like most other inhalation aerosol products, Beclomethasone aerosol may be less effective at low temperatures. When the canister cools down, it is recommended to remove it from the plastic case and warm it with your hands for a few minutes.
Features of the action of the drug upon its withdrawal
Due to the risk of exacerbation, sudden o.g. should be avoided. The dose of the drug should be reduced gradually under the supervision of a physician.
Beclomethasone-aeronativ, 250 mcg/dose, 200 doses, dosed aerosol for inhalation, 1 pc.
Inhalation.
Bronchial asthma
Adults and children aged 12 years and older. Beclomethasone aeronate is used regularly (even in the absence of symptoms of the disease), the dose of beclomethasone dipropionate is selected taking into account the severity of bronchial asthma and the clinical effect in each specific case. The daily dose is divided into several doses.
Recommended initial doses of the drug:
— mild bronchial asthma — 200–600 mcg/day;
— moderate bronchial asthma — 600–1000 mcg/day;
- severe bronchial asthma - 1000–2000 mcg/day.
Children aged 4 to 12 years. Up to 400 mcg/day in several doses.
Depending on the patient's individual response, the dose of the drug can be increased until a clinical effect appears or reduced to the minimum effective dose.
When switching to a high dose of inhaled beclomethasone dipropionate in many patients receiving systemic corticosteroids, it is possible to reduce their dose or discontinue them completely.
COPD
The maximum recommended dose of Beclomethasone-aeronativ for COPD is 2000 mcg/day.
If you accidentally miss an inhalation, the next dose must be taken at the scheduled time in accordance with the treatment regimen.
Administration can be carried out using special dispensers (spacers), which improve the distribution of the drug in the lungs and reduce the risk of side effects.
Special patient groups
Patients with impaired liver function.
In patients with impaired liver function, no dose reduction is required.
Patients with impaired renal function.
In patients with impaired renal function, no dose reduction is required.
Instructions for inhalation
Beclomethasone aeronative is intended for inhalation use only.
Before using the inhaler for the first time or if the inhaler has not been used for a week or longer, you should check its operation. To do this, remove the protective cap from the mouthpiece of the inhaler, shake the inhaler well and press the balloon, releasing one stream of the drug into the air.
Carrying out inhalation
Step 1. Remove the protective cap from the inhaler mouthpiece, as shown in Figure 1.
Step 2: Shake the inhaler vigorously.
Step 3. Exhale slowly and completely.
Step 4. Holding the balloon as shown in Figure 2, tightly wrap your lips around the mouthpiece. The cylinder should be directed upside down.
Step 5. Inhale as deeply as possible, while quickly pressing the bottom of the balloon until one inhalation dose is released.
Step 6. Hold your breath for a few seconds, then remove the mouthpiece from your mouth and exhale slowly.
Step 7. Place the protective cap on the mouthpiece of the inhaler.
Repeat steps 3–6 to receive a second inhalation dose, if necessary.
After inhalation, it is recommended to rinse your mouth and throat with water. Do not swallow water.
Cleaning the inhaler
The inhaler mouthpiece should be cleaned regularly (once a week), as shown in Figure 3.
Remove the metal can from the plastic case and rinse the case and cap with warm water. Do not use hot water. Dry thoroughly, but do not use heating devices for this. Place the can back into the case and put on the cap. Do not immerse the metal can in water.
Beclomethasone-aeronativ aeroz 250 µg/dose 200 doses (Nativa)
Before prescribing inhaled drugs, it is necessary to instruct the patient on the rules for their use, ensuring the most complete delivery of the drug to the desired areas of the lungs. To prevent oral candidiasis, after inhalation you should rinse your mouth and throat with water. To treat candidiasis, topical antifungal drugs can be used while continuing Beclomethasone-aeronativ therapy. If patients take GCS orally, then Beclomethasone-aeronative is prescribed while taking the previous dose of GCS, and the patients should be in a relatively stable condition. After about 1 to 2 weeks, the daily dose of oral corticosteroids begins to be gradually reduced. The dose reduction scheme depends on the duration of previous therapy and the size of the initial dose of GCS. Regular use of inhaled GCS allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be completely transferred to inhaled therapy), while in the first months after the transition the patient’s condition should be carefully monitored until his pituitary-adrenal the system will not recover sufficiently to provide an adequate response to stressful situations (such as injury, surgery, or infection). When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema) that were previously suppressed by systemic drugs may occur. Patients with reduced function of the adrenal cortex, transferred to inhalation treatment, should have a supply of GCS and always carry a warning card with them, the LP 002051-150413 of which should indicate that in stressful situations they need additional systemic administration of GCS (after eliminating the stressful situation The dose of GCS can be reduced again). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, often life-threatening for patients, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting b2-agonists than before. Beclomethasone aeronative is not intended for the relief of attacks, but for regular daily use. To relieve attacks, short-acting b2-agonists (for example, salbutamol) are used. In case of severe exacerbation of bronchial asthma or insufficient effectiveness of the therapy, the dose of the drug "Beclomethasone-aeronativ" should be increased and, if necessary, a systemic corticosteroid and/or an antibiotic should be prescribed if the infection develops. If paradoxical bronchospasm develops, you should immediately stop using Beclomethasone Aeronative, assess the patient’s condition, conduct an examination and, if necessary, prescribe therapy with other drugs. With long-term use of any inhaled corticosteroids, especially in high doses, systemic effects may be observed (see “Side effects”), but the likelihood of their development is much lower than when taking corticosteroids orally. Therefore, it is especially important that when a therapeutic effect is achieved, the dose of inhaled corticosteroids is reduced to the minimum effective dose that controls the course of the disease. At a dose of 1500 mcg/day, the drug does not cause significant suppression of adrenal function in most patients. Due to possible adrenal insufficiency, special care should be taken and regular monitoring of adrenal function indicators when transferring patients taking oral corticosteroids to treatment with Beclomethasone-Aeronativ. Sharp o. is not recommended. Particular care should be taken when treating patients with active or inactive forms of pulmonary tuberculosis with inhaled corticosteroids. It is necessary to protect the eyes from contact with the drug. By washing after inhalation you can prevent damage to the skin of the eyelids and nose. The can of Beclomethasone Aeronative must not be pierced, disassembled or thrown into a fire, even if it is empty. Like most other inhalation aerosol products, Beclomethasone aerosol may be less effective at low temperatures. When the canister is cooling, it is recommended to remove it from the plastic LP 002051-150413 case and warm it with your hands for several minutes. Peculiarities of the action of the drug when it is discontinued Due to the risk of exacerbation, sudden withdrawal should be avoided. The dose of the drug should be reduced gradually under the supervision of a physician. Effect on the ability to drive vehicles and operate machinery Beclomethasone-aeronativ does not affect the ability to drive vehicles and operate machinery.
